The research, published in the journal Supportive Care in Cancer, compared two ways of administering photobiomodulation therapy, a technique that uses low-level lasers to stimulate tissue healing and reduce inflammation. In the intraoral approach, the laser is applied directly inside the mouth, touching the mucosa at dozens of precisely mapped points. In the extraoral approach, light is delivered from outside the cheek and lips, requiring no mouth opening and no contact with sensitive tissue. A team led by researchers at the Federal University of Paraná and Erasto Gaertner Hospital in Curitiba found that when families experienced both methods, nearly two-thirds preferred the extraoral technique, driven overwhelmingly by one factor: comfort.

The study enrolled pediatric patients aged eighteen or younger who were being treated for leukemia, lymphoma, or osteosarcoma with high-dose methotrexate, a chemotherapy drug strongly associated with mucositis. Because the trial used a crossover design, every child received both forms of photobiomodulation during successive chemotherapy cycles, typically spaced three weeks apart. Treatment began before the methotrexate infusion and continued daily until hospital discharge, with a median of four sessions per cycle. After experiencing both modalities, parents and caregivers completed a structured nine-item questionnaire about their preferences, the discomfort they observed, and their impressions of how well each method controlled pain.

The technical contrast between the two protocols was striking. The intraoral protocol, adapted from guidelines issued by the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology, required irradiation at forty-two separate points distributed across the buccal mucosa, the tongue, the floor of the mouth, the lips, and the soft palate. Light delivery alone took roughly seven minutes, with total clinical time stretching from twenty to forty minutes. The extraoral device, by comparison, used eight emitters firing simultaneously, four lateral ones delivering 4.30 joules per square centimeter and four central ones delivering 34.50 joules per square centimeter, across just three anatomical regions: the orbicularis oris muscle and the left and right buccinator muscles. Each region received ten seconds of irradiation, and the entire appointment lasted five to ten minutes.

The results were unambiguous on the question of tolerability. Discomfort during application was reported by 43.8 percent of caregivers for the intraoral method but only 6.3 percent for the extraoral method, a difference that reached statistical significance with a p-value of 0.001 using McNemar’s test for paired comparisons. When asked which modality they preferred, 65.6 percent chose the extraoral approach, citing greater comfort and the advantage of not needing to hold the mouth open. This matters enormously in pediatric oncology, where children may suffer from trismus, pain, or simply limited cooperation during mucositis episodes, making prolonged intraoral procedures difficult or impossible to complete.

Yet the story grew more nuanced when the researchers examined perceptions of pain control. Although families preferred the extraoral device for its comfort, 34.4 percent believed the intraoral method provided better pain relief, compared with only 12.5 percent who favored the extraoral route for analgesia. The authors offer a plausible biophysical explanation: when light must traverse multiple tissue barriers from outside the face, some energy is dissipated before reaching the target tissue, potentially weakening the analgesic effect. Differences in the severity and distribution of mucositis lesions between cycles may also have confounded how caregivers judged pain relief. Notably, however, these subjective impressions did not correspond to measurable differences in the occurrence or severity of oral mucositis between the two modalities.

Indeed, half of the children in the sample developed oral mucositis during follow-up, and no statistically significant association emerged between the preferred modality and mucositis occurrence. The researchers are careful to frame this as exploratory rather than as proof that the two methods are clinically equivalent, given the small sample of thirty-two respondents and a 15.6 percent rate of missing data caused by the inability to link some online questionnaire responses to clinical records. The study was also not prospectively registered, lacked a formal sample-size calculation for the questionnaire component, and relied on retrospective caregiver recall, all of which introduce the possibility of bias, particularly recency effects from the most recent treatment cycle.

What the findings do establish, the authors argue, is that acceptance and tolerability deserve a seat at the table when clinicians choose supportive care protocols. Photobiomodulation is already recommended by international guidelines for preventing oral mucositis in adults receiving head and neck radiotherapy or hematopoietic stem cell transplantation, but pediatric protocols remain fragmented, with no consensus on optimal dosimetric parameters. Because the therapy must be repeated daily across several days of hospitalization, the cumulative burden of an uncomfortable procedure compounds quickly. The extraoral approach also avoids direct contact with ulcerated tissue, which may reduce the risk of opportunistic infections in immunocompromised children and simplifies clinical logistics in busy inpatient units.

The Brazilian results align with a growing international literature. Earlier feasibility studies of extraoral photobiomodulation in pediatric inpatient settings reported successful daily prophylaxis without pain or treatment interruption, and a combined intraoral-extraoral therapeutic protocol achieved success in 77 percent of mucositis episodes with no adverse events. A recent multicenter randomized trial in adults with head and neck cancer found no relevant differences between the two routes in mucositis severity, lesion duration, or functional impairment. In the absence of evidence that one delivery method is clinically superior, one research group has suggested that the best parameter set may simply be the one that is fastest and most comfortable for the patient, a principle the new caregiver data strongly reinforce.

For the roughly 34 percent of families in the study who still preferred the intraoral method, and for the caregivers who perceived it as more effective at controlling pain, the trade-off is not trivial. The authors emphasize that perceived efficacy in their study reflects subjective impressions, not measured clinical outcomes, and they call for larger, prospectively designed trials to settle questions of comparative effectiveness. But their central message is one that resonates far beyond laser dentistry: in pediatric medicine, the treatment a child can tolerate day after day may be the treatment that ultimately works best. When a therapy’s success depends on repeated administration in patients too young, too sick, or too sore to cooperate, comfort is not a luxury. It is a clinical variable, and one that the extraoral laser, in this study at least, decisively won.

Subject of Research: Acceptance and perceived efficacy of intraoral versus extraoral photobiomodulation for preventing oral mucositis in pediatric oncology patients

Article Title: Acceptance and perceived efficacy of intraoral versus extraoral photobiomodulation for oral mucositis prevention in pediatric patients

Article References: Acceptance and perceived efficacy of intraoral versus extraoral photobiomodulation for oral mucositis prevention in pediatric patients. (n.d.). https://doi.org/10.1007/s00520-026-11227-3

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11227-3

Keywords: photobiomodulation, oral mucositis, pediatric oncology, low-level laser therapy, chemotherapy side effects, supportive care, high-dose methotrexate, caregiver-reported outcomes, extraoral laser, intraoral laser, treatment tolerability, MASCC/ISOO guidelines

The team conducted a scoping review, a study design intended to chart the breadth and quality of existing evidence rather than pool it into a single statistical estimate. The researchers searched PubMed, EBSCO, CINAHL, Ovid and Google Scholar for studies published between May 2012 and February 2025, structuring their search around the PICO framework—population, intervention, comparison, outcome—and assessed the methodological rigor of each study using the quality assessment tools developed by the United States National Heart, Lung, and Blood Institute. The haul amounted to 35 individual investigations: 27 randomized controlled trials, three randomized pilot studies, four pre-post studies and one case series. That breadth matters, because perineal pain is not a niche complaint. Assisted deliveries, episiotomies and perineal lacerations all increase both the intensity of pain and the amount of medication women need afterward, making effective conservative options a genuine public health question.

The clearest signal in the review came from an almost old-fashioned remedy. Eight studies supported cold therapy—ice packs, cold gel pads and similar applications—for short-term relief of perineal pain. The technique is physiologically plausible: cooling the tissue slows local nerve conduction, reduces swelling and dampens inflammatory signaling in the damaged perineal wound. The catch, the authors note, is that the studies used markedly different protocols, varying in how long the cold was applied, how often, and with what devices. Without standardized treatment regimens, clinicians have little guidance on how to translate the positive findings into practice, even though the direction of the evidence is consistent and the intervention carries essentially no pharmacological risk to a nursing mother.

Light-based therapies produced a far more skeptical verdict. Five studies examined light therapy, split between low-level laser therapy and far-infrared radiation, and most showed no superiority over placebo or no treatment. Low-level laser therapy delivers non-thermal red and near-infrared light intended to stimulate cellular repair, while far-infrared devices emit gentle radiant heat; neither convincingly outperformed sham treatment in the trials reviewed. This stands in contrast to the enthusiasm that light-based wound-healing devices sometimes attract, and it underscores a recurring theme of the review: plausible mechanisms do not guarantee clinical benefit, and rigorous randomized comparisons frequently deflate early promise.

Electricity fared considerably better. Four trials of transcutaneous electrical nerve stimulation, or TENS, showed the technique’s superiority over placebo despite varying stimulation protocols. TENS works through electrodes placed on the skin that deliver low-voltage electrical pulses, thought to activate inhibitory pain pathways in the spinal cord—the gate-control mechanism that competes with pain signals before they reach consciousness. Trials tested both high-frequency and low-frequency stimulation, and while protocols were again inconsistent, the consistent finding across studies was meaningful pain reduction. For women reluctant to take any systemic drug in the early postpartum days, a wearable electrical device offers an appealing, drug-free adjunct or alternative.

Radiofrequency therapy, a less familiar option to most patients, also emerged as a candidate worth watching. Two randomized controlled trials of radiofrequency treatment reported reduced perineal pain and discomfort in certain positions. The reviewed studies included capacitive and resistive energy transfer systems, which heat deeper tissue layers to promote circulation and healing. The evidence base is thin—just two trials—but both pointed in the same direction, prompting the authors to place radiofrequency alongside cold therapy and TENS among the most promising conservative treatments. One additional study found therapeutic ultrasound delivered with gel pads more effective than gel pads alone or laser therapy, adding a further physical modality to the shortlist, though a single trial is far from definitive.

Temperature-based care during and after labor received mixed marks. Two studies found that heat therapy applied during labor was effective for short-term pain relief, and two observational studies examined water immersion, but the latter were judged to be of low quality, leaving their findings uncertain. One study that combined cold application, heat application and pelvic floor muscle training showed significant benefits lasting up to seven days after delivery, suggesting that multi-component conservative care may outperform any single technique. Intriguingly, the reviewers found that no study has yet tested pelvic floor muscle training on its own for postpartum perineal pain relief—an conspicuous gap, given how widely the exercises are prescribed for pelvic floor recovery after childbirth.

The review was less kind to hands-on and needle-based traditions. A single study of manual therapy produced results the authors described as unclear, and its quality was rated low. Seven trials of acupuncture and acupressure—needle stimulation and finger pressure at defined points, respectively—were of poor to fair methodological quality, with mixed findings on whether the techniques reduced pain or the need for pain medication. With no high-quality randomized evidence to lean on, the reviewers declined to endorse these approaches, a sobering conclusion for a family of therapies often assumed to be well supported. Similarly, the single study touching on osteopathic manipulative treatment left the question of its value essentially open.

The methodological weaknesses that run through the evidence base are as important as any individual result. Only a minority of the 35 studies were fully powered randomized controlled trials, blinding is inherently difficult when the treatment involves visible ice packs or electrical devices, and outcome measures varied from visual analogue and numerical rating scales to composite wound-healing scores such as the REEDA scale and questionnaires on postpartum comfort and sexual function. The authors’ conclusion is deliberately cautious: the evidence supports cold therapy, TENS and radiofrequency as emerging options, but the limited number of robust studies means clinicians and patients should interpret even the positive findings carefully until larger, protocol-standardized trials are completed.

Still, the practical implications are significant for a condition that touches nearly every vaginal delivery. Perineal pain in the first weeks after birth interferes with breastfeeding, infant care, sleep, mobility and early sexual recovery, and up to 37 percent of affected women rate their pain as moderate to severe even while taking conventional analgesics. A structured, evidence-informed toolkit of cooling, electrical stimulation and possibly radiofrequency could meaningfully reduce reliance on opioids and other systemic drugs at a time when many mothers are anxious about medication passing into breast milk. The Gdańsk team’s review does not declare any of these treatments a cure, but it does something arguably more useful: it separates the therapies with converging randomized evidence from those riding on hype, and it lays out exactly where the next generation of trials should focus. For postpartum women and the clinicians who care for them, the message is that sometimes the most effective medicine for childbirth’s most common overlooked pain may be found not in the pharmacy, but in the freezer, the physiotherapy suite and the low-voltage electrode.

Subject of Research: Non-pharmacological management of postpartum perineal pain

Article Title: When analgesics are not enough for postpartum perineal pain—a scoping review of the non-pharmacological, conservative therapies

Article References: Wojtas, J., Sotomska, Z., Pietrzak, J., Waldman, A., Wydra, D., & Grzybowska, M. E. (2026). When analgesics are not enough for postpartum perineal pain—a scoping review of the non-pharmacological, conservative therapies. BMC Complementary Medicine and Therapies. https://doi.org/10.1186/s12906-026-05544-7

Image Credits: AI Generated

DOI: 10.1186/s12906-026-05544-7

Keywords: postpartum perineal pain, cold therapy, TENS, radiofrequency, scoping review, pain management, non-pharmacological therapies, low-level laser therapy, acupuncture, acupressure, pelvic floor, childbirth recovery

The study, conducted by a team of Egyptian researchers from Cairo University, enrolled twenty-two patients with confirmed oral pemphigus vulgaris and randomly assigned them into two equal groups. Both groups continued their standard systemic therapy, typically the immunosuppressive medication backbone that pemphigus care depends on. The experimental group, however, also received low-level laser therapy, or LLLT, applied three times weekly for four weeks directly to the oral lesions. The control group received systemic treatment alone. The design was deliberately simple and clinically relevant: the question was not whether lasers could replace drugs, but whether they could meaningfully augment them.

Low-level laser therapy, sometimes called photobiomodulation, is fundamentally different from the surgical lasers most people imagine. Instead of cutting or vaporizing tissue, these low-energy diode devices deliver light at intensities low enough to avoid heating or damaging cells. The photons are absorbed by chromophores inside mitochondria, particularly components of the respiratory chain, which is thought to boost cellular energy production, modulate inflammatory signaling and stimulate the proliferation of fibroblasts and endothelial cells. Decades of research have explored this mechanism in wound healing, ulcer care and pain management, and the pemphigus field had already seen intriguing case reports and small pilot studies hinting at benefit. What was missing was controlled trial data in oral pemphigus specifically, which is precisely the gap this study set out to fill.

The researchers assessed outcomes using a battery of complementary measures. Ulcer size was tracked by measuring changes in lesion length, and pain was quantified with the visual analog scale, the standard patient-reported tool in which zero represents no pain and ten the worst imaginable discomfort. Disease severity in the mouth was scored with the Pemphigus Oral Lesions Intensity Score, known as POLIS, a validated instrument designed specifically for grading the intensity of oral pemphigus lesions. To probe the biology beneath the clinical surface, the team also measured tissue levels of tumor necrosis factor alpha, a pro-inflammatory cytokine central to autoimmune inflammation, using enzyme-linked immunosorbent assay. Every measurement was taken before treatment began and again after the four-week course, allowing within-patient and between-group comparisons.

The most striking results concerned ulcers and pain. Patients who received the combined laser-plus-medication regimen showed significantly greater reductions in ulcer length and significantly lower visual analog scale scores than those on medication alone, with both differences reaching a p-value below 0.001. In practical terms, the laser-treated group saw their wounds shrink faster and their day-to-day pain drop more steeply over the four weeks. For a disease in which oral pain is often the single most disabling complaint, that finding carries real weight. Faster mucosal healing also matters beyond comfort, because open oral ulcers can impair nutrition and serve as gateways for secondary infection in patients whose immune systems are already dampened by systemic therapy.

The picture was more nuanced for overall disease severity. Both groups experienced significant decreases in their POLIS scores after four weeks, with p-values of 0.006 in the laser group and 0.003 in the control group, reflecting the fact that standard systemic therapy does work on its own. However, the difference in POLIS improvement between the two groups did not reach statistical significance, registering at p equal to 0.101. This suggests that the laser’s clearest contribution was to the local problems, ulcer size and pain, rather than to the global intensity score of oral lesions over this relatively short treatment window. It is a distinction that matters for clinicians deciding what the laser is actually adding to the therapeutic equation.

The inflammatory biomarker told a similar story of direction without decisive divergence. Tumor necrosis factor alpha levels decreased within each group over the treatment period, consistent with the anti-inflammatory effect of systemic pemphigus therapy and possibly with photobiomodulation’s immunomodulatory reputation. Yet when the researchers compared the percent change between the laser group and the control group, the difference was not statistically significant. The study was small, with only eleven patients per arm, and modest sample sizes limit the power to detect subtle shifts in molecular markers. The cytokine data therefore remain hypothesis-generating rather than conclusive, and larger trials with longer follow-up would be needed to establish whether laser therapy measurably dampens the inflammatory cascade in pemphigus tissue.

Satisfaction and physician assessment added an interesting human dimension. Patient satisfaction scores were similar between the two groups, but the physician global assessment scores differed significantly between groups, and the authors noted that patients in the laser group were more satisfied. The divergence between patient and physician ratings is a reminder that healing trajectories and subjective experience do not always move in lockstep, and that instruments capturing different perspectives can disagree even within the same trial. The authors also emphasized tolerability, reporting that the therapy was safe and well accepted, which is a crucial consideration for patients already managing the considerable side-effect load of long-term corticosteroids and immunosuppressants.

The trial’s limitations deserve honest acknowledgment. Twenty-two patients is a small cohort, and the four-week follow-up captures early response rather than long-term control of a disease that often requires months to years of management. The study also did not report blinding details in a way that would fully eliminate performance bias, which is inherently difficult when one group can feel the laser device at work. Still, the randomized design, the use of validated outcome instruments such as POLIS and the visual analog scale, and the objective measurement of ulcer dimensions and cytokine levels give the findings a credibility that earlier case reports could not achieve. The results align with a growing literature on photobiomodulation in oral inflammatory disease, including randomized work in recurrent aphthous stomatitis and pilot studies of laser therapy in pemphigus lesions.

What does this mean for patients and clinicians today? The evidence supports low-level diode laser therapy as a safe, well-tolerated adjunct that can accelerate ulcer healing and reduce pain in oral pemphigus vulgaris when layered on top of standard systemic treatment, not as a replacement for it. For a condition in which the oral cavity is frequently the first and most stubborn site of involvement, a noninvasive, drug-free tool that targets exactly that site is an appealing addition to the therapeutic arsenal. Larger, blinded, longer-duration trials will be needed before laser sessions become routine in pemphigus clinics worldwide, but this trial moves photobiomodulation from anecdote toward evidence, and offers a glimpse of a future in which light itself becomes part of the prescription for one of medicine’s most painful autoimmune diseases.

Subject of Research: Low-level laser therapy as an adjunctive treatment for oral pemphigus vulgaris

Article Title: Efficacy and tolerability of low-level diode laser therapy as an adjunctive in the treatment of oral pemphigus vulgaris, a randomized controlled trial

Article References: Efficacy and tolerability of low-level diode laser therapy as an adjunctive in the treatment of oral pemphigus vulgaris, a randomized controlled trial. (n.d.). https://doi.org/10.1007/s00403-026-04875-2

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04875-2

Keywords: pemphigus vulgaris, low-level laser therapy, photobiomodulation, diode laser, oral ulcers, wound healing, pain management, TNF alpha, autoimmune blistering disease, randomized controlled trial, POLIS score, visual analog scale